



## REGENXBIO Announces Presentation at the Barclays Gene Editing & Therapy Summit 2023

May 22, 2023 11:05 AM EDT

ROCKVILLE, Md., May 22, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present in a fireside chat and panel as well as host one-on-one investor meetings at the Barclays Gene Editing & Therapy Summit 2023 on Wednesday, May 24, 2023.

### Barclays Gene Editing & Therapy Summit 2023

**Date:** Wednesday, May 24, 2023

**Fireside Chat:** 9:15 a.m. ET

**Panel:** Genomic Medicines – Are We Ready for Commercialization? – Perspective from Payors at 2:40 p.m. ET

A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at [www.regenxbio.com](http://www.regenxbio.com). An archived replay of the fireside chat and panel will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.

### About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

### Contacts:

Dana Cormack  
Corporate Communications  
[dcormack@regenxbio.com](mailto:dcormack@regenxbio.com)

Investors:  
Chris Brinzey  
ICR Westwicke  
339-970-2843  
[chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-the-barclays-gene-editing--therapy-summit-2023-301830445.html>

SOURCE REGENXBIO Inc.